Logo
x

Search

Subscribe Now

Kisqali

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

  • September 22, 2020
Insights+: Breakthrough Therapy Designation by the US FDA in 2018

Insights+: Breakthrough Therapy Designation by the US FDA in 2018

  • May 8, 2019
Novartis Reports P-III Trial (NATALEE) Results of Kisqali (ribociclib) for the Treatment of Early Breast Cancer

    Novartis Reports P-III Trial (NATALEE) Results of Kisqali (ribociclib) for the Treatment of Early Breast Cancer

    • March 27, 2023
    Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

      Novartis Reports P-III (MONALEESA-2/3/7) Study Results of Kisqali (ribociclib) for HR+/HER2- Advanced Breast Cancer

      • September 9, 2022
      Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer

        Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advan...

        • May 5, 2022
        Novartis

          Novartis' Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

          • September 22, 2020
          Insights+: Breakthrough Therapy Designation by the US FDA in 2018

            Insights+: Breakthrough Therapy Designation by the US FDA in 2018

            • May 8, 2019
            Image

            Incisive News in 3 Shots.

            Contact Us

            Our Information

            Follow Us

            Copyright © 2025 PharmaShots - All Rights Reserved.